GigaMune is a therapeutics company developing a novel technology for in vivo, T cell targeted gene delivery of T cell receptors (TCRs) and chimeric antigen receptors (CARs) for serious diseases such as cancer and autoimmune diseases. Our initial goal is to challenge conventional ex vivo cell therapy manufacturing by reducing costs and improving outcomes. Our eventual goal is to deliver any gene to any cell in any tissue location at any time. See our high throughput immune screening technology highlighted in Nature Biotechnology (DOI: 10.1038/s41587-020-0438-y), and our petabase-scale protein search algorithm, published in Nature (DOI: 10.1038/s41586-021-04332-2).
Company Details
- Employees
- 10
- Founded
- 2017
- Address
- 953 Indiana St, San Francisco,california 94107,united States
- Industry
- Biotechnology
- Website
- gigamune.com
- HQ
- San Francisco, California
Gigamune Questions
Gigamune's website is gigamune.com
Gigamune's LinkedIn profile is https://www.linkedin.com/company/gigamune
Gigamune has
10 employees.
View email and phone details for 10
employees at Gigamune.
Gigamune's industry is
Biotechnology
Gigamune's top competitors are
Revitope,
Arcus Biosciences,
Arsenal Biosciences, Inc.,
Grifols,
Freenome,
Gigagen Inc,
Boost Vc,
Gritstone Bio,
Kyverna Therapeutics,
El Poblenou Llc.
Gigamune's categories are Biotechnology
Gigamune's founding year is 2017
